GuruFocus.com2d agobullish
AbCellera Stock Jumps 33% on a Positive Menopause TrialThe Phase 2 trial met both primary endpoints on symptom frequency and severity
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
328last 24h
2140last 7d
379● bullish (7d)
188● bearish (7d)
204publishers
InvestorsHub2d agobullish
AbCellera shares surge 22% after ABCL635 delivers positive Phase 2 resultsAbCellera (NASDAQ:ABCL) shares jumped 22% on Monday after the biotechnology company announced positive topline results from a Phase 2 clinical trial evaluating ABCL635 as a potential treatment for moderate-to-severe vasomotor symptoms associated with menopause. The study achieved its primary efficacy endpoints, demonstrating statistically significant reductions in both the frequency and severity of moderate-to-severe vasomotor symptoms at week four following a single dose compared with placebo.
Zacks8d agobullish
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 ViewJazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
Stocktwits45d agobullish
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
Zacks48d agobullish
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks56d agobullish
Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
Zacks65d agobullish
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Insider Monkey82d agobullish
Here’s Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long TermAbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 12, 2026, Stifel raised the firm’s price target on AbCellera Biologics Inc. (NASDAQ:ABCL) to $8 from $7 and kept a Buy rating on the shares. The firm said preliminary safety, pharmacokinetic, and pharmacodynamic data from the […]
Zacks82d agobullish
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks93d agobullish
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue EstimatesABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?